Clinical Insights
home
contact
about usprincipal investigatorclinical trialsinterest formdirections
About Us
Clinical Trials ExperienceAssessment ExperiencePharmaceutical Sponsors

Clinical Trials Experience

2002

  • Study Drug Once Daily Dosing Versus Placebo in Patients with Major Depression and Pain

  • Study Drug Versus Placebo in Generalized Anxiety Disorder. A Randomized Double-Blind Placebo- and Buspirone-Controlled Fixed-Dose Parallel Group Multicenter Study of 10 Weeks (Including a 2-week Single-Blind Placebo Period)

  • A Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy of Study Drug in the Treatment of Premenstrual Dysphoric Disorder (PMDD)

  • Study Drug plus Study Drug in Combination for Treatment-Resistant Depression without Psychotic Features

  • A Prospective Multi-Center Open-Label Study of Study Drug in the Management of Patients with Schizophrenia or Schizoaffective Disorder in General Psychiatric Practice

  • A Phase III Randomized Double-Blind Placebo-Controlled Outpatient Study to Assess the Long-Term Safety and Efficacy of Two Dose Levels of a Modified Release Formulation of Study Drug in Adult Patients with Primary Insomnia

  • Study Drug in the Treatment of Generalized Anxiety Disorder. An Open Multicenter Safety Study of 5 Months, Including a 1-Month Drug Free Follow-Up Period. Follow Up to GAD Study

  • An 8-week Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multi Center, Fixed Dose Study Comparing the Efficacy and Safety of Study Drug or Study Drug to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder
Clinical Insights
Clinical Insights
Clinical Insights 1600 Crain Highway South - Suite 601 - Glen Burnie, MD 21061 - 410.768.2629 Clinical Insights 1600 Crain Highway South - Suite 601 - Glen Burnie, MD 21061 - 410.768.2629